Kanay Yararbaş

Kanay Yararbaş

Auto-generated profile, based on publicly available information

Kanay Yararbaş

Department of Medical Genetics, Demiroglu Bilim University, Faculty of Medicine, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Urology Research and Practice
Verified
Journal Article
Closed access
STSemih Tangal
Semih Tangal
YTYasemin Tasci
Yasemin Tasci
EPEmre Göksan Pabuçcu
Emre Göksan Pabuçcu
GÇGamze Sinem Çağlar
Gamze Sinem Çağlar
AHAhmet Hakan Haliloğlu
Ahmet Hakan Haliloğlu
KYKanay Yararbaş
Kanay Yararbaş
Objective: This study was designed to evaluate the prevalence of Human Papilloma Virus (HPV) in semen and document the cycle outcomes in couples with previous intra-cytoplasmic sperm injection (ICSI) failures. Material and methods: One hundred and seventeen couples with at least two ICSI attempts were included in the study. HPV infection in semen and DNA fragmentation in samples were analyzed by commercially available kits. The percentage of spermatozoa with fragmented DNA (DNA fragmentation index: DFI) was determined during fluorescence microscopic examination as previously described. The cycle outcomes of couples with or without HPV infected male partners were recorded. Results: According to our results, the prevalence of HPV was 7.7% in asymptomatic males with at least two previous ICSI failures. The increased DFI (>30%) was observed in 82.9% of the cases. In HPV-positive cases significantly lower number of good quality embryos were obtained. The implantation and pregnancy rates were similar in infected and non-infected males (p>0.05). The early miscarriage rate was slightly higher in HPV- positive group (33% vs. 10%, p>0.05). Conclusion: In cases with previous ICSI failures, the prevalence of HPV infection in semen is not higher than previously reported infertile populations. The reproductive outcome might be impaired in HPV-positive semen due to lower number of good quality embryos, which needs to be clarified by further large population-based studies. Cite this article as: Tangal S, Taşçı Y, Pabuçcu EG, Çağlar GS, Haliloğlu AH, Yararbaş K. DNA fragmentation index and human papilloma virus in males with previous assisted reproductive technology failures. Turk J Urol 2019; 45(1): 12-6.

16 July 2021 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
HKHande Kaymakcalan
Hande Kaymakcalan
IKİlYas Kaya
İlYas Kaya
NBNagihan Cevher Binici
Nagihan Cevher Binici
ENEmrah Nikerel
Emrah Nikerel
BÖBurcu Özbaran
Burcu Özbaran
AEAdife Gulhan Ercan‐Sencicek
Adife Gulhan Ercan‐Sencicek
Background: Phosphatase and tensin homolog (PTEN) germline mutations are associated with cancer syndromes (PTEN hamartoma tumor syndrome; PHTS) and in pediatric patients with autism spectrum disorder (ASD) and macrocephaly. The exact prevalence of PTEN mutations in patients with ASD and macrocephaly is uncertain; with prevalence rates ranging from 1% to 17%. Most studies are retrospective and contain more adult than pediatric patients, there is a need for more prospective pediatric studies.Methods: We recruited 131 patients (108 males, 23 females) with ASD and macrocephaly between the ages of 3 and 18 from five child and adolescent psychiatry clinics in Turkey from July 2018 to December 2019. We defined macrocephaly as occipito‐frontal HC size at or greater than 2 standard deviations (SD) above the mean for age and sex on standard growth charts. PTEN gene sequence analysis was performed using a MiSeq next generation sequencing (NGS) platform, (Illumina).Conclusion: PTEN gene sequence analyses identified three pathogenic/likely pathogenic mutations [NM_000314.6; p.(Pro204Leu), (p.Arg233*) and novel (p.Tyr176Cys*8)] and two variants of uncertain significance (VUS) [NM_000314.6; p.(Ala79Thr) and c.*10del]. We also report that patient with (p.Tyr176Cys*8) mutation has Grade 1 hepatosteatosis, a phenotype not previously described. This is the first PTEN prevalence study of patients with ASD and macrocephaly in Turkey and South Eastern Europe region with a largest homogenous cohort. The prevalence of PTEN mutations was found 3.8% (VUS included) or 2.29% (VUS omitted). We recommend testing for PTEN mutations in all patients with ASD and macrocephaly.

23 June 2023 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
ÇÜÇağlar Ünal
Çağlar Ünal
GTGulsah Tuncer
Gulsah Tuncer
BÇBetül Çopur
Betül Çopur
KPKezban Nur Pilanci
Kezban Nur Pilanci
KOKEREM OKUTUR
KEREM OKUTUR
Çetin OrduÇetin Ordu
Çetin Ordu
We aimed to identify a rapid, accurate and accessible biomarker in the early stages of COVID-19 that can determine the prognosis of the disease in cancer patients. A total number of 241 patients with solid cancers who had COVID-19 diagnosis between March 2020 and February 2022 were included in the study. Factors and markers of inflammation were analyzed by year of diagnosis of COVID-19 and grouped by severity of infection. Hospitalization, referral to the intensive care unit (ICU), mechanical ventilation and death were more frequent in 2020 than in 2021 and 2022. (mortality rates respectively 18.8%, 3.8% and 2.5%) Bilateral lung involvement and chronic lung disease were independent risk factors for severe disease in 2020. In 2021-2022, only bilateral lung involvement was found as an independent risk factor for severe disease. The neutrophil to lymphocyte, platelet ratio (NLPR) with the highest area under the curve (AUC) value in 2020 had a sensitivity of 71.4% and specificity of 73.3% in detecting severe disease (cut-off > 0.0241, Area Under the Curve (AUC) =0.842, p < 0.001). In 2021-2022, the sensitivity of the C-reactive protein to lymphocyte ratio (CRP/L) with the highest AUC value was 70.0%, and the specificity was 73.3% (cut-off > 36.7, AUC = 0.829, p = 0.001). This is the first study to investigate the distribution and characteristics of cancer patients diagnosed with COVID-19. Based on the data from our study, bilateral lung involvement is an independent factor for severe disease, and the CRP/L inflammation index appears to be the most reliable prognostic marker.

19 October 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ÇÜÇağlar Ünal
Çağlar Ünal
Çetin OrduÇetin Ordu
Çetin Ordu
TÖTolga Özmen
Tolga Özmen
AIAhmet Serkan İlgun
Ahmet Serkan İlgun
FÇFiliz Çelebi
Filiz Çelebi
VÖVahit Özmen
Vahit Özmen
Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive than those of E2, FSH, and inhibin B and that AFC and MOV can be used to evaluate ovarian reserve. AMH, AFC, and MOV measurements were performed before and after adjuvant SC in 3-month periods for one year. Patients were classified as experiencing chemotherapy-induced amenorrhea (CIA) if they did not have menstrual cycles for a period of six months or longer following the conclusion of their chemotherapy treatment. We aimed to evaluate the factors affecting chemotherapy-induced amenorrhea in breast cancer patients treated with adjuvant chemotherapy and the performance of baseline measurements of AMH, AFC, and MOV to predict chemotherapy-induced amenorrhea. The effects of different chemotherapy regimens on the AMH level, AFC, and MOV in CIA patients were investigated. Seventy-one patients were eligible for this study, and the median age was 38 years (range: 23–45). The median follow-up was 37 months (range: 20–51), and CIA developed in 62% of the patients. The AMH level and AFC were significantly decreased one year after SC (p < 0.0001), whereas MOV was not (p = 0.507). AMH levels before chemotherapy (median: 1.520 vs. 0.755, p = 0.001) and at the end of the first year (median: 0.073 vs. 0.010, p = 0.030) and pre-treatment AFC (median: 12 vs. 4.50, p = 0.026) were lower in patients with CIA compared to those without CIA. The AMH levels before SC were the most valuable and earliest factor for predicting CIA development. In addition, there was no difference between the chemotherapy regimens (including or not including taxane) in terms of CIA development.

14 May 2025 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
IUIpek Ulkersoy
Ipek Ulkersoy
ACAhsen Colakoglu
Ahsen Colakoglu
EPEymen Pinar
Eymen Pinar
EKEce Kuduban
Ece Kuduban
EAErkan Akkuş
Erkan Akkuş
FCFugen Cullu Cokugras
Fugen Cullu Cokugras

5 June 2013 in Turkish Journal of Hematology
Verified
Journal Article
Open access
AAAyça Dilruba Aslanger
Ayça Dilruba Aslanger
AAAynur Akbulut
Aynur Akbulut
GTGül Tokgöz
Gül Tokgöz
STSakine Türkmen
Sakine Türkmen
KYKanay Yararbaş
Kanay Yararbaş